Mainz Biomed NV

4TO

Company Profile

  • Business description

    Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company’s flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.

  • Contact

    Robert Koch Strasse 50
    Sirius Gutenberg Park
    MainzRP55129
    DEU

    T: +49 61315542860

    https://www.mainzbiomed.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Diagnostics & Research

    Fiscal Year End

    31 December 2025

    Employees

    26

Stocks News & Analysis

stocks

Undervalued ASX income play

Major development projects remain on schedule.
stocks

Going into earnings, is Alphabet stock a buy, a sell, or fairly valued?

With the monetization of GenAI, here’s what we think of Alphabet’s stock
stocks

Going into earnings, Is Meta stock a buy, a sell, or fairly valued?

With a focus on leveraging its AI investments, here’s what we think of Meta stock.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,941.5015.300.17%
CAC 407,763.3834.84-0.45%
DAX 4024,119.80188.00-0.77%
Dow JONES (US)44,323.0719.12-0.04%
FTSE 1009,012.390.60-0.01%
HKSE25,130.03135.890.54%
NASDAQ20,974.1878.520.38%
Nikkei 22539,774.9244.19-0.11%
NZX 50 Index12,833.74127.77-0.99%
S&P 5006,305.608.810.14%
S&P/ASX 2008,677.209.000.10%
SSE Composite Index3,581.8622.070.62%

Market Movers